ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency

  • Auteur/autrice de la publication :
  • Post category:Newsroom

Erytech Pharma announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease.